PATENT CLAIM ANALYSIS

Application Number: 15755411
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-09
Patent Classification: ["514", "367000"]

Abstract:
The invention relates to antibacterial compounds of formula I wherein R 1 , M, R 2 , R 3 , and V are as described in the description, to their preparation, to salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula I, and especially to their use as antibacterial agents.

Claim (Index 1):
A compound of formula I wherein V represents O or S;\n R 2  and R 3  each independently represent hydrogen or fluorine; and \n M is one of the groups M A  and M B  represented below \n wherein in group M A :\n A represents a bond or \u2014C\u2261C\u2014; \n R 1A  represents hydrogen, or halogen; \n R 2A  represents hydrogen, or halogen; and \n R 3A  represents\n (C 1 -C 3 )alkoxy; \n hydroxy(C 1 -C 4 )alkyl; or\n R NA1 R NA2 N\u2014(C 1 -C 3 )alkyl, wherein R NA1  and R NA2  independently represent hydrogen or (C 1 -C 3 )alkyl; or R NA1  and R NA2  together with the nitrogen to which they are attached form a 4- to 6-membered saturated ring optionally containing one oxygen ring atom, wherein said ring is unsubstituted, or mono-substituted with fluoro; and \n \n \n wherein in group M B :\n R 1B  represents\n hydroxy(C 1 -C 4 )alkyl; \n 1-(3-hydroxyazetidine)-1-carbonyloxymethyl; \n 1-hydroxymethyl-cycloprop-1-yl, or a group which is a prodrug thereof wherein said group is 1-((phosphonooxy)methyl)-cycloprop-1-yl, 1-[(di(C 1 -C 4 )alkylamino)-(C 1 -C 3 )alkyl-carbonyloxymethyl]-cycloprop-1-yl, 1-{[(2-(phosphonooxy-(C 1 -C 4 )alkyl)-phenyl)-(C 1 -C 4 )alkyl]-carbonyloxymethyl}-cycloprop-1-yl, 1-{[2-(phosphonooxy-(C 1 -C 4 )alkyl)-phenyl]-carbonyloxymethyl}-cycloprop-1-yl, or 1-{[(2-phosphonooxy-phenyl)-(C 1 -C 4 )alkyl]-carbonyloxymethyl}-cycloprop-1-yl; \n trans-2-hydroxymethyl-cycloprop-1-yl, or a group which is a prodrug thereof wherein said group is trans-2-(phosphonooxymethyl)-cycloprop-1-yl, trans-2-[(di(C 1 -C 4 )alkylamino)-(C 1 -C 3 )alkyl-carbonyloxymethyl]-cycloprop-1-yl, trans-2-{[(2-(phosphonooxy-(C 1 -C 4 )alkyl)-phenyl)-(C 1 -C 4 )alkyl]-carbonyloxymethyl}-cycloprop-1-yl, trans-2-{[2-(phosphonooxy-(C 1 -C 4 )alkyl)-phenyl]-carbonyloxymethyl}-cycloprop-1-yl, or trans-2-{[(2-phosphonooxy-phenyl)-(C 1 -C 4 )alkyl]-carbonyloxymethyl}-cycloprop-1-yl; \n 2-fluoro-2-hydroxymethyl-cycloprop-1-yl, or a group which is a prodrug thereof wherein said group is 2-fluoro-2-(phosphonooxymethyl)-cycloprop-1-yl, 2-fluoro-2-[(di(C 1 -C 4 )alkylamino)-(C 1 -C 3 )alkyl-carbonyloxymethyl]-cycloprop-1-yl, 2-fluoro-2-{[(2-(phosphonooxy-(C 1 -C 4 )alkyl)-phenyl)-(C 1 -C 4 )alkyl]-carbonyloxymethyl}-cycloprop-1-yl, 2-fluoro-2-{[2-(phosphonooxy-(C 1 -C 4 )alkyl)-phenyl]-carbonyloxymethyl}-cycloprop-1-yl, or 2-fluoro-2-{[(2-phosphonooxy-phenyl)-(C 1 -C 4 )alkyl]-carbonyloxymethyl}-cycloprop-1-yl; \n 3-hydroxy-oxetan-3-yl; \n trans-2-(1,2-dihydroxyethyl)cycloprop-1-yl; \n trans-(cis-3,4-dihydroxy)-cyclopent-1-yl; \n R NB1 R NB2 N\u2014(C 1 -C 3 )alkyl, wherein R NB1  and R NB2  independently represent hydrogen or (C 1 -C 3 )alkyl; \n 1-(R NB3 R NB4 N)-cycloprop-1-yl, wherein R NB3  and R NB4  independently represent hydrogen or (C 1 -C 3 )alkyl, or R NB3  represents hydrogen and R NB4  (phosphonooxy)methoxy-carbonyl; \n azetidin-3-yl, wherein said azetidin-3-yl is unsubstituted, or mono- or di-substituted wherein, if present,\n one substituent is attached in position 1 of said azetidin-3-yl group, wherein said substituent is selected from (C 1 -C 3 )alkyl, (C 3 -C 4 )cycloalkyl, oxetan-3-yl, \u03c9-fluoro-(C 2 )alkyl, or \u03c9-hydroxy-(C 2 -C 4 )alkyl; and/or \n one substituent is fluoro attached in position 3 of said the azetidin-3-yl group; \n \n \n R 1  represents hydrogen, or R 1  represents \u2014PO 3 H 2 , \u2014SO 3 H, phosphonooxymethyl, or the group L represented below \n wherein R 4  represents (C 1 -C 4 )alkylamino(C 1 -C 4 )alkyl, di(C 1 -C 4 )alkylamino(C 1 -C 4 )alkyl, phosphonooxy(C 1 -C 4 )alkyl, phosphonooxymethoxy, 2-(phosphonooxy-(C 1 -C 4 )alkyl)-phenyl, [2-(phosphonooxy-(C 1 -C 4 )alkyl)-phenyl]-(C 1 -C 4 )alkyl, or (2-(phosphonooxy)-phenyl)-(C 1 -C 4 )alkyl;\n or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 88.0
- Lexical Diversity: 1.69231
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15756366', '15123184', '15021649', '15106790', '15311758']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8237945881371309
- 35 USC 102 Novelty (BERT): 0.6058849666133107
- Combined Prediction Score: 0.8020036259847488
- Mean Citation Score: 511.932564
- Max Citation Score: 532.57104
- Similarity Product: 473.2447803481865

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test